Metals Surge on Copper Boom, IT Services Shine as Market Halts

COMMODITIES
Whalesbook Logo
AuthorAarav Shah|Published at:
Metals Surge on Copper Boom, IT Services Shine as Market Halts
Overview

Indian equity benchmarks remained largely flat midday, with the Nifty holding above 25,300 and the Sensex unchanged. However, significant sectoral divergence was observed. Hindustan Copper experienced a dramatic surge driven by soaring copper prices on global exchanges. eClerx Services gained on strong quarterly earnings and a bonus issue announcement, while ABB India climbed on positive news from its Swiss parent and robust domestic order growth. Hindalco Industries also advanced, buoyed by expansion plans amid a favourable metals environment.

The Commodity Surge

The Indian equity market found a plateau midday, with the Nifty hovering around the 25,300 mark and the Sensex exhibiting zero movement. This broad market inertia stood in stark contrast to the vigorous price action seen in specific sectors, most notably metals. Hindustan Copper dominated trading, its stock jumping close to 19.5%. This rally is an extension of a multi-month ascent, with the stock having already climbed over 190% in the past six months [cite: Scraped News]. The primary impetus was the surge in copper futures on the Multi Commodity Exchange of India (MCX), which climbed over 6% to a lifetime high, mirroring international price trends driven by demand from electric vehicles, renewable energy, and data centres [cite: Scraped News]. This surge has pushed Hindustan Copper's P/E ratio to approximately 129 as of January 2026, significantly higher than the broader metals sector P/E of around 18.28. The company, a sole vertically integrated copper producer in India, holds access to approximately 45% of India's copper ore reserves. Despite a high valuation, its recent stock performance suggests strong investor conviction aligned with commodity price trends.

Earnings and Strategic Moves Fuel Select Stocks

Beyond commodities, corporate performance metrics also drove significant stock movements. eClerx Services saw robust buying interest, rising around 8%, following the release of its December quarter results. The company reported a nearly 40% year-on-year increase in net profit and strong revenue growth, complemented by a 1:1 bonus issue announcement [cite: Scraped News]. While specific valuation multiples for eClerx were not immediately available, such results typically underscore operational efficiency and shareholder value enhancement.

ABB India also experienced a substantial rally, climbing approximately 9%, marking one of its strongest sessions in recent months [cite: Scraped News]. This upward momentum was directly linked to its Swiss parent, ABB Ltd., reporting a strong Q4 2025 close, with the Indian market proving a major contributor. Notably, ABB India's parent disclosed a significant 49% year-on-year increase in order inflow for the Indian region, surpassing analyst expectations. This performance is set against a backdrop where ABB India's market capitalization stands around ₹1.07 trillion with a P/E ratio of approximately 57-60 as of January 2026. Competitors like Siemens India trade at a P/E of ~44.3, and L&T around 30-35, placing ABB India at a higher valuation multiple, but its substantial order backlog of ₹9,380 crore as of December 2024 provides visibility into future revenue streams. Analysts maintain a neutral consensus with an average price target near ₹5,498, suggesting limited immediate upside from current levels.

Sectoral Resilience and Mixed Outlooks

Hindalco Industries traded higher by 2.5% to 3% after announcing progress on its aluminium operations expansion in Odisha [cite: Scraped News]. This development, while operational, gained traction within the currently favoured metals sector. With firm aluminium prices and renewed interest in industrial metals, Hindalco's expansion plans offer a positive signal for medium-term capacity growth.

Piramal Pharma saw a modest increase of nearly 3% following its third-quarter results. The company's performance was described as steady, which, combined with increased trading volumes, contributed to the positive market response [cite: Scraped News]. However, recent analyses highlight a TTM P/E ratio of approximately -862.05, indicating investor concerns over recent profitability, despite a market capitalization of around ₹20,504 crore. Competitors in the pharmaceutical sector, such as Dr. Reddy's Laboratories (P/E ~17-19) and Divi's Laboratories (P/E ~64-73), present varied valuation pictures. While Piramal Pharma has shown good historical profit and revenue growth over three years, recent results have indicated margin contraction and net losses, though the company reaffirms its FY26 guidance. Analyst sentiment for Piramal Pharma is mixed, with some adjusting price targets upwards, reflecting a complex outlook for the company within the generally stable Indian pharmaceutical sector projected for 7-9% growth in FY2026.

Disclaimer:This content is for educational and informational purposes only and does not constitute investment, financial, or trading advice, nor a recommendation to buy or sell any securities. Readers should consult a SEBI-registered advisor before making investment decisions, as markets involve risk and past performance does not guarantee future results. The publisher and authors accept no liability for any losses. Some content may be AI-generated and may contain errors; accuracy and completeness are not guaranteed. Views expressed do not reflect the publication’s editorial stance.